Published in J Chromatogr on March 05, 1993
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet (1998) 2.85
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother (1997) 2.57
HIV infection as leading cause of death among young adults in US cities and states. JAMA (1993) 2.47
Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet (1997) 2.34
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother (1998) 2.23
Sociodemographics and HIV risk behaviors of bisexual men with AIDS: results from a multistate interview project. AIDS (1993) 2.13
HIV testing patterns: where, why, and when were persons with AIDS tested for HIV? AIDS (1995) 2.12
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (1997) 2.08
Race/ethnicity misclassification of persons reported with AIDS. The AIDS Mortality Project Group and The Supplement to HIV/AIDS Surveillance Project Group. Ethn Health (1996) 2.05
The reporting of HIV/AIDS deaths in women. Am J Public Health (1992) 1.89
Socioeconomic differences among people with AIDS: results from a Multistate Surveillance Project. Am J Prev Med (1995) 1.87
The supplement to HIV-AIDS Surveillance project: an approach for monitoring HIV risk behaviors. Public Health Rep (1996) 1.85
Health insurance coverage among persons with AIDS: results from a multistate surveillance project. Am J Public Health (1994) 1.63
Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992. Ann Intern Med (1995) 1.60
Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother (1998) 1.60
Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol (2011) 1.57
Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos (1999) 1.56
Intramuscular and intravenous pharmacokinetics of cefmenoxime, a new broad-spectrum cephalosporin, in healthy subjects. Antimicrob Agents Chemother (1982) 1.55
Difloxacin metabolism and pharmacokinetics in humans after single oral doses. Antimicrob Agents Chemother (1986) 1.48
Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med (1992) 1.46
Differences in participation in experimental drug trials among persons with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.42
Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther (1998) 1.40
Changes in AIDS incidence for men who have sex with men, United States 1990-1995. AIDS (1997) 1.39
Cefsulodin kinetics in renal impairment. Clin Pharmacol Ther (1982) 1.37
Assessing HIV risk among women who have sex with women: scientific and communication issues. J Am Med Womens Assoc (1995) 1.36
Recent developments in HIV protease inhibitor therapy. Antiviral Res (1998) 1.33
AIDS-associated Kaposi's sarcoma. Science (1995) 1.28
Risk behaviors of persons with heterosexually acquired HIV infection in the United States: results of a multistate surveillance project. J Acquir Immune Defic Syndr (1994) 1.28
Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol (1998) 1.27
Nutrient intakes in relation to cancer incidence in Hawaii. Br J Cancer (1981) 1.21
Who are the primary caretakers of children born to HIV-infected mothers? Results from a multistate surveillance project. Pediatrics (1995) 1.19
The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology (1985) 1.18
Surveillance for thrombocytopenia in persons infected with HIV: results from the multistate Adult and Adolescent Spectrum of Disease Project. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.17
Cefsulodin kinetics in healthy subjects after intramuscular and intravenous injection. Clin Pharmacol Ther (1982) 1.14
Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. The Adult and Adolescent Spectrum of HIV Disease Project Group. Arch Intern Med (1995) 1.14
Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrob Agents Chemother (1998) 1.13
Surveillance for AIDS and HIV infection among black and Hispanic children and women of childbearing age, 1981-1989. MMWR CDC Surveill Summ (1990) 1.12
Years of potential life lost due to HIV infection in the United States. AIDS (1997) 1.11
The migration of persons with AIDS: data from 12 states, 1985 to 1992. AIDS Mortality Project Group. Am J Public Health (1995) 1.10
The types of drugs used by HIV-infected injection drug users in a multistate surveillance project: implications for intervention. Am J Public Health (1994) 1.07
A very precise high-performance liquid chromatographic procedure for the determination of cefmenoxime, a new cephalosporin antibiotic, in plasma. J Chromatogr (1982) 1.06
Crack cocaine use and sexual behavior among people with AIDS. JAMA (1993) 1.05
Oxidative metabolism of polycyclic aromatic hydrocarbons to ultimate carcinogens. Drug Metab Rev (1982) 1.03
Risk factors for regret after tubal sterilization: 5 years of follow-up in a prospective study. Fertil Steril (1991) 1.03
Effect of cimetidine on the pharmacokinetics of temafloxacin. Clin Pharmacokinet (1992) 1.03
Living situation of women with AIDS. J Acquir Immune Defic Syndr (1993) 1.01
Pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther (1998) 1.00
AIDS deaths shift from hospital to home. AIDS Mortality Project Group. Am J Public Health (1993) 0.98
HIV wasting syndrome in the United States. AIDS (1993) 0.96
A comparison of frequency and quantitative dietary methods for epidemiologic studies of diet and disease. Am J Epidemiol (1984) 0.96
Precise high-performance liquid chromatographic procedure for the determination of cefsulodin, a new antipseudomonal cephalosporin antibiotic, in plasma. J Pharm Sci (1982) 0.95
How important is race/ethnicity as an indicator of risk for specific AIDS-defining conditions? J Acquir Immune Defic Syndr Hum Retrovirol (1995) 0.95
Injection and syringe sharing among HIV-infected injection drug users: implications for prevention of HIV transmission. Supplement to HIV/AIDS Surveillance Group. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 0.94
Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. Clin Pharmacokinet (1992) 0.93
Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. Clin Pharmacokinet (1995) 0.92
Imaging findings in mandibular primitive neuroectodermal tumour: a report of a rare case and review of the literature. Dentomaxillofac Radiol (2011) 0.91
Sensitive method for the assay of sertindole in plasma by high-performance liquid chromatography and fluorimetric detection. J Chromatogr B Biomed Appl (1994) 0.91
Characteristics of women 50 years of age or older with heterosexually acquired AIDS. Am J Public Health (1996) 0.91
Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl (1995) 0.91
Update: epidemiology of reported cases of AIDS in women who report sex only with other women, United States, 1980-1991. AIDS (1992) 0.91
Female-to-female sexual contact and HIV transmission. JAMA (1994) 0.91
Surveillance of AIDS-defining conditions in the United States. Adult/Adolescent Spectrum of HIV Disease Project Group. AIDS (1994) 0.89
Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics. J Clin Pharmacol (1993) 0.89
Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid. Clin Infect Dis (2001) 0.87
Characterization of small monoclonal protein bands with Beckman's "Paragon" immunofixation system. Clin Chem (1987) 0.87
Toxoplasmic encephalitis in HIV-infected persons: risk factors and trends. The Adult/Adolescent Spectrum of Disease Group. AIDS (1996) 0.86
Enantioselective determination of DN-2327, a novel non-benzodiazepine anxiolytic, and/or its active metabolite in human plasma and urine using high-performance liquid chromatography. J Chromatogr (1993) 0.86
Dietary fat intake and cancer incidence among five ethnic groups in Hawaii. Cancer Res (1981) 0.86
The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine. Clin Pharmacokinet (1995) 0.84
Relationship between use of condoms and other forms of contraception among human immunodeficiency virus-infected women. Supplement to HIV and AIDS Surveillance Project Group. Obstet Gynecol (1995) 0.84
Acquired immunodeficiency syndrome in the United States associated with injecting drug use, 1981-1991. Am J Drug Alcohol Abuse (1993) 0.84
High-performance liquid chromatographic procedures for the determination of difloxacin and its metabolites in biological matrices. J Chromatogr (1987) 0.83
Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Clin Pharmacokinet (1995) 0.83
Oral health problems and use of dental services among HIV-infected adults. Supplement to HIV/AIDS Surveillance Project Group. J Am Dent Assoc (1997) 0.83
Hepatobiliary elimination of temafloxacin. Clin Pharmacokinet (1992) 0.82
Aspects of the metabolism of valproic acid. Xenobiotica (1984) 0.82
Effect of pentoxifylline on intraperitoneal adhesions after intestinal resection in rats. J Formos Med Assoc (1995) 0.82
High-performance liquid chromatographic procedure for the determination of tiagabine concentrations in human plasma using electrochemical detection. J Chromatogr (1992) 0.81
Biological actions of monoclonal luteinizing hormone/human chorionic gonadotropin receptor antibodies. Biol Reprod (1992) 0.81
Kinetic studies of adenosine kinase from Ehrlich ascites tumor cells. J Biol Chem (1972) 0.81
Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin Pharmacol Ther (1996) 0.81
Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol (1993) 0.80
Methodological and statistical considerations for exercise-related hormone evaluations. Sports Med (1995) 0.80
Surveillance during an era of rapidly changing poliovirus epidemiology in India: the role of one vs. two stool specimens in poliovirus detection, 2000-2010. Epidemiol Infect (2013) 0.80
Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics. Clin Pharmacokinet (1992) 0.79
Characteristics of women who considered or obtained tubal reanastomosis: results from a prospective study of tubal sterilization. Obstet Gynecol (1990) 0.79
Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant. J Inherit Metab Dis (2002) 0.79
The hepatotoxicity of valproic acid and its metabolites in rats. II. Intermediary and valproic acid metabolism. Hepatology (1985) 0.79
A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology (1997) 0.79
Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur J Clin Pharmacol (1997) 0.79
Pharmacokinetics of a clarithromycin suspension in infants and children. Antimicrob Agents Chemother (1992) 0.79
Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers. Biopharm Drug Dispos (1997) 0.79
Effect of three-day clot contact on results of common biochemical tests with serum. Clin Chem (1986) 0.79
The pharmacokinetics of zileuton in healthy young and elderly volunteers. Clin Pharmacokinet (1995) 0.79
HIV and trends in cervical cancer death rates among young women. Am J Public Health (1993) 0.79
The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers. Clin Pharmacokinet (1995) 0.78